TD Asset Management
CRSP icon

TD Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

TD Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.78M Sell
142,602
-15,814
-10% -$834K 0.01% 711
2026
Q1 		$7.54M Hold
158,416
– – 0.01% 715
2025
Q4 		$8.31M Sell
158,416
-16,200
-9% -$970K 0.01% 703
2025
Q3 		$11.3M Sell
174,616
-53,800
-24% -$3.09M 0.01% 629
2025
Q2 		$11.1M Sell
228,416
-13,904
-6% -$538K 0.01% 619
2025
Q1 		$8.25M Buy
242,320
+1,876
+0.8% +$79.5K 0.01% 686
2024
Q4 		$9.46M Buy
240,444
+80,800
+51% +$3.82M 0.01% 658
2024
Q3 		$7.55M Hold
159,644
– – 0.01% 695
2024
Q2 		$8.62M Sell
159,644
-7,150
-4% -$414K 0.01% 645
2024
Q1 		$11.4M Sell
166,794
-59,068
-26% -$4.23M 0.01% 605
2023
Q4 		$14.1M Sell
225,862
-14,600
-6% -$807K 0.01% 556
2023
Q3 		$10.9M Buy
240,462
+27,387
+13% +$1.41M 0.01% 571
2023
Q2 		$12M Buy
213,075
+3,069
+1% +$174K 0.01% 555
2023
Q1 		$9.5M Buy
210,006
+28,179
+15% +$1.37M 0.01% 619
2022
Q4 		$7.39M Buy
181,827
+66,536
+58% +$3.53M 0.01% 658
2022
Q3 		$7.43M Buy
115,291
+11,630
+11% +$843K 0.01% 661
2022
Q2 		$6.3M Buy
103,661
+71,636
+224% +$4.21M 0.01% 721
2022
Q1 		$2.01M Sell
32,025
-2,248
-7% -$141K ﹤0.01% 1084
2021
Q4 		$2.6M Buy
34,273
+3,876
+13% +$339K ﹤0.01% 1073
2021
Q3 		$3.4M Hold
30,397
– – ﹤0.01% 931
2021
Q2 		$3.68M Sell
30,397
-999
-3% -$121K ﹤0.01% 917
2021
Q1 		$3.83M Sell
31,396
-312
-1% -$47.1K ﹤0.01% 903
2020
Q4 		$4.86M Buy
+31,708
New +$3.75M 0.01% 794

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TD Asset Management's CRSP Position: Q2 2026 in Review

TD Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 10% in Q2 2026, selling an estimated $834K and leaving 142,602 shares worth $7.78M. The position accounts for 0.01% of the portfolio, ranked #711.

TD Asset Management first reported a position in CRSP in Q4 2020 and has held it in 23 quarters since. The position peaked at $14.1M in Q4 2023. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • TD Asset Management held 142,602 shares of CRISPR Therapeutics worth $7.78M as of Q2 2026.
  • TD Asset Management sold 15,814 CRISPR Therapeutics shares in Q2 2026, an estimated $834K.
  • CRISPR Therapeutics made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #711 holding.
  • TD Asset Management first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • TD Asset Management's CRISPR Therapeutics position peaked at $14.1M in Q4 2023.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.